<DOC>
	<DOCNO>NCT01409499</DOCNO>
	<brief_summary>The standard treatment choice advance hepatocellular carcinoma ( HCC ) sorafenib , efficacy limit . More active treatment perform patient advanced HCC China , include radical hepatectomy TACE . The study investigate whether active treatment profit survival patient , evaluate safety .</brief_summary>
	<brief_title>Palliative Treatments Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>This prospective non-randomized control study . Patients advance hepatocellular carcinoma ( BCLC C stage ) underwent palliative resection TACE follow Sorafenib treat sorafenib alone include . The patient divide group A ( palliative resection plus sorafenib ) , group B ( palliative TACE plus sorafenib ) , group C ( sorafenib alone ) . The sample size 200 case altogether .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female patient &gt; 18 year age . Diagnosed advanced HCC ( BCLC C stage ) . Patients life expectancy least 12 week . Patients whose primary tumor resect . Definition resectable study : Tumor number &lt; =2 . If number tumor &gt; = 3 , tumor locate lobe . Without tumor invasion main trunk portal vein , hepatic duct , caval vein . Hepatocellular carcinoma histological diagnose clinical diagnose accord AASLD . No major postoperative complication . Patients ECOG PS 0 , 1 . Cirrhotic status ChildPugh class A . The following laboratory parameter : Platelet count &gt; 60 x 109/L Hemoglobin &gt; 8.5 g/dL Albumin &gt; 3.5 g/dL Total bilirubin &lt; 25μmol/L Alanine transaminase ( ALT ) AST &lt; 2.5 x upper limit normal Serum creatinine &lt; 1.5 x upper limit normal Prothrombin time ( PT ) &lt; 3 second control . • Patients give write informed consent . Previous concurrent cancer distinct primary site histology HCC . History cardiac disease . Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . History organ allograft . Known suspected allergy investigational agent agent give association trial . Pregnant breastfeeding patient . Any condition unstable could jeopardize safety patient his/her compliance study . Excluded therapy medication , previous concomitant : Systemic chemotherapy target drug sorafenib . Antiviral treatment allow . Radiotherapy except do bone metastases palliatively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatocellular carcinoma , treatment , survival</keyword>
</DOC>